A Software Company
Formed March 2015
Open for Business
Adding Clients & Partners
Cancer Genomics Software with Unique Algorithms
MatchTx provides a SaaS solution that helps researchers, oncologists and clinical trial managers identify the full set of biomarkers that collectively predict the outcome of cancer patients to treatments. Patent-pending algorithms classify millions of combinations of genomic and clinical data to find the full set predictive biomarkers (Deep Genetic Signatures™) from reference data sets. The Signatures are used to identify the previous tumors ‘most like my patient’s cancer’ to match therapeutics based on real patient outcomes, not just population averages.
Prostate Cancer, Biliary Tract Cancer, Sarcomas and other tumor types
Analyzing thousands of cancer cases with M2Gen and ORIEN
Licensed from OSU
Ongoing collaboration with Ohio State and James Cancer Center
Growing our business
Our cloud-hosted product platform and and our team of healthcare IT software developers and data scientists are ready work with you on your project, your clinical trial, or your patients.
Pilot Project Studies
Our solution is commercially available. We often start with pilot projects on qualified cancer patient data studies in a shared risk manner- contact us so that we can begin working together.
We have not lost our academic roots. If you have data sets, software tools, or grant opportunities, please contact us.
Matching Therapeutics to Cancer Patients™
Personalizing Precision Medicine using Deep Genetic Signatures™
Jeff Wilt (CPA), COO/CFO – Over 30 years as senior executive managing healthcare software companies. Successfully led development, business operations, and nationwide sales of healthcare software that integrated with EMR systems. Jeff has a personal stake in MatchTx, having recently lost a close family member (daughter) to cancer at the James Cancer Center, OSU. Wilt is dedicated to lead day to day business and sales operations and provide business management expertise around finance and project management.
Dr. James Chen (MD), the inventor of the technology, is Assistant Professor in Biomedical Informatics and in Internal Medicine at OSU and a translational oncologist with extensive bioinformatics experience. He is also a Founder and serves as Director of Precision Medicine of MatchTx. He is involved in all aspects of developing and commercializing the technology. Dr. Chen was recently named Chair-Elect for the ASCO Health Information Committee and ASCO Liaison to the Global Alliance for Genomics and Health.
Dr. Jeff Spitzner, CEO, has over 20 years’ experience as a founder and executive of eight scientific software and bio-technology companies that contributed over $30 Million to the Columbus, OH community. Spitzner won 2011 Executive of the Year Innovation Award and has experiences in equity fundraising, product vision and management, strategic marketing, sales management, business development, and executive leadership. He raised millions of dollars in equity investment for previous ventures. His businesses sold clinical research solutions to the same set of organizations targeted for MatchTx. Jeff received his Ph.D. (molecular cancer research and bioinformatics) from The Ohio State University, then did post-doctoral work at MIT. Spitzner led pioneering technology development and commercialization efforts in areas including bioinformatics and human genome research. Spitzner also partnered with Ohio State and Signet Enterprises to facilitate commercialization of the University’s collaborative Healthcare IT platform as Signet Accel. As CEO, he manages the growth and business activities of MatchTx.
Software Development, Data Sciences, and Customer Support.
MatchTx has assembled an excellent team to grow and support the product and our customers. Please contact us if you wish to become part our great team.
311 Kendall PL
Columbus, OH 43205
Please email us to arrange a call or web meeting